In May alone, Isomorphic Labs, a London-based artificial intelligence drug discovery firm, secured $2.1 billion in Series B funding—a striking validation of how biotech is betting its future on computational biology. The investment, led by Thrive Capital and Alphabet itself, signals that the wave of AI-driven medicine has moved from speculation into serious capital deployment across the sector.
The 2026 fundraising landscape reveals a global biotech ecosystem intensely focused on three frontiers: cancer immunotherapy, autoimmune disease, and the algorithmic redesign of how drugs get made. What's noteworthy is not just the scale of the capital—billions flowing into venture-backed biopharma—but where it's flowing and why. The most competitive space appears to be cell and gene therapy for cancer, where multiple companies are expanding their clinical footprint with newly minted funding rounds exceeding $100 million.
Isomorphic's $2.1 billion haul stands out as exceptional, but it's part of a broader pattern. The company, founded in 2021 within Alphabet, brought in $600 million in external funding just a year prior and has now doubled down on developing next-generation artificial intelligence drug design capabilities. That trajectory—from AI-native founding to billion-dollar scaling—mirrors the sector's conviction that computational methods will fundamentally reshape drug discovery timelines and success rates.
Across the sector, the ticket sizes reveal where investor confidence is concentrated. Create Medicines, which has dosed more than 50 patients in trials of its in vivo CAR-T cancer candidates and claims "the largest clinical dataset in the field," raised $122 million in Series B funding in mid-May to expand its autoimmune and cancer pipelines. Ray Therapeutics secured $125 million to advance vision restoration candidates for retinal degeneration. Coultreon Biopharma, a Belgian company that launched in 2025 by acquiring shipwrecked assets from Galapagos, raised $125 million in Series A to push its autoimmune lead candidate from early-stage testing into phase 2 trials for psoriasis and ulcerative colitis.
The geographic spread matters too. Accro Bioscience, based in Suzhou, China, raised $50 million in Series C to fund a phase 2b trial of its RIPK2 inhibitor for ulcerative colitis—now expanding from China and Australia into U.S. patients. Vivacta Biotechnology, a Chinese in vivo CAR-T company, raised $50 million in April to advance its lead candidate GT801 through clinical trials and toward regulatory submission, having first presented human data at the American Society of Hematology annual meeting in December.
What ties these rounds together is ambition operating at scale. Tortugas Neuroscience, launched by Sage Therapeutics veterans with a clinical-stage pipeline licensed from Eisai and Hansoh Pharmaceutical, raised $106 million in seed and Series A funding to advance candidates for schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. Cytospire Therapeutics, a London-based biotech, raised £61 million to bring its gamma delta T-cell engager into clinical trials for solid tumors.
The 2026 tracker—monitoring rounds of $50 million and above—reveals an industry placing enormous bets that precision approaches to immunotherapy, AI-designed molecules, and expanded patient datasets will translate scientific breakthroughs into medicines that matter. Whether this capital deployment fulfills its promise will define biotech's next decade.